Key facts
- It has raised $7.6M across 5 recorded rounds; the latest was Seed Round ($500K) in Feb 2025.
- Notable investors include Archer Venture Capital, Recurring Capital Partners, Frontier Venture Capital, Simulations Plus.
- Nurocor has filed 7 Form Ds with the SEC since 2022, most recently May 2025 ($460K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nurocor
Funding rounds
5 roundsAbout Nurocor
Developer of digital clinical development tools designed for transforming document-based processes into structured data workflows. The company's platform supports protocol design, standards management, and digital asset governance through microservices and shared services like access control and audit trails, enabling pharmaceutical and life sciences organizations to accelerate study design, improve regulatory readiness, and enhance collaboration across teams.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 57
- Website
- nurocor.com/
- Ownership
- Privately Held (backing)
Nurocor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nurocor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nurocor in its N-PORT filings yet. We sweep new filings monthly.